Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer.

Formestane is a selective inhibitor of oestrogen synthesis by aromatase enzymes and induces disease regression in breast cancer patients. This phase II randomised study was carried out to determine whether there were any differences in the effects of two different doses of formestane on oestradiol (...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajetta, E., Zilembo, N., Buzzoni, R., Noberasco, C., Di Leo, A., Bartoli, C., Merson, M., Sacchini, V., Moglia, D., Celio, L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033308/
https://www.ncbi.nlm.nih.gov/pubmed/8018527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033308/
https://www.ncbi.nlm.nih.gov/pubmed/8018527

Ejemplares similares